Exploiting radiation immunostimulatory effects to improve glioblastoma outcome. Issue 3 (14th October 2022)

• Record Type: Journal Article
• Authors: Awada, Hala; Paris, François; Pecqueur, Claire
• Is Part Of: Neuro-oncology. Volume 25:Issue 3(2023)
• Page Start: 433
• Page End: 446
• Publication Date: 2022-10-14
• Subjects: glioblastoma -- immunomodulation -- radiotherapy; Brain Neoplasms -- Periodicals; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481
• DOI: 10.1093/neuonc/noac239
• Languages: English
• ISSNs: 1522-8517

Abstract

Abstract: Cancer treatment protocols depend on tumor type, localization, grade, and patient. Despite aggressive treatments, median survival of patients with Glioblastoma (GBM), the most common primary brain tumor in adults, does not exceed 18 months, and all patients eventually relapse. Thus, novel therapeutic approaches are urgently needed. Radiotherapy (RT) induces a multitude of alterations within the tumor ecosystem, ultimately modifying the degree of tumor immunogenicity at GBM relapse. The present manuscript reviews the diverse effects of RT radiotherapy on tumors, with a special focus on its immunomodulatory impact to finally discuss how RT could be exploited in GBM treatment through immunotherapy targeting. Indeed, while further experimental and clinical studies are definitively required to successfully translate preclinical results in clinical trials, current studies highlight the therapeutic potential of immunotherapy to uncover novel avenues to fight GBM.